PureTech Health plc (LSE: PRTC)
Health Care · Biotechnology · US
£1.13
+1.44% today · -15.0% 1Y
PureTech Health plc (LSE: PRTC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $360.13M and employs 56 people.
Over the last twelve months the share price has lost 15.0%, trading between 1.07 and 1.44.
Tweenvest scores PureTech Health plc across four factors: quality 42/100, value 50/100, growth 0/100. Its strongest factor is value.
PRTC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $360.13M
- Revenue (TTM)
- $6.37M
- P/E
- 188.72
- EPS
- 0.01
- Dividend yield
- —
- Beta (5Y)
- 0.81
- 52-week high
- £1.44
- 52-week low
- £1.07
- Avg volume (3M)
- —
- Shares outstanding
- 245.18M
- Employees
- 56
- Next earnings
- —
About PureTech Health plc
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
- ISIN
- GB00BY2Z0H74
- Founded
- 2015
- Listed since
- Jun 19, 2015
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| C4 Therapeutics, Inc.NasdaqGS: CCCC | $376.46M | $3.06 | -3.16% |
| Fennec Pharmaceuticals Inc.NasdaqCM: FENC | $375.57M | $10.72 | +0.09% |
| Hansa Biopharma AB (publ)OM: HNSA | $365.97M | Skr36.12 | +0.44% |
| ProKidney Corp.NasdaqCM: PROK | $363.53M | $1.67 | -4.02% |
| Inhibikase Therapeutics, Inc.NasdaqCM: IKT | $358.69M | $1.85 | -6.35% |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | $358.24M | $12.30 | -1.60% |
| Emergent BioSolutions Inc.NYSE: EBS | $357.89M | $6.98 | -1.13% |
| Cuorips Inc.TSE: 4894 | $353.89M | ¥6,310.00 | +0.80% |
Figures last refreshed Oct 11, 2026.